Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 858

1.

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.

Savale L, Guignabert C, Weatherald J, Humbert M.

Eur Respir Rev. 2018 Apr 13;27(148). pii: 180004. doi: 10.1183/16000617.0004-2018. Print 2018 Jun 30.

2.

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension.

Gräf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, Hodgson J, Liu B, Salmon RM, Southwood M, Machado RD, Martin JM, Treacy CM, Yates K, Daugherty LC, Shamardina O, Whitehorn D, Holden S, Aldred M, Bogaard HJ, Church C, Coghlan G, Condliffe R, Corris PA, Danesino C, Eyries M, Gall H, Ghio S, Ghofrani HA, Gibbs JSR, Girerd B, Houweling AC, Howard L, Humbert M, Kiely DG, Kovacs G, MacKenzie Ross RV, Moledina S, Montani D, Newnham M, Olschewski A, Olschewski H, Peacock AJ, Pepke-Zaba J, Prokopenko I, Rhodes CJ, Scelsi L, Seeger W, Soubrier F, Stein DF, Suntharalingam J, Swietlik EM, Toshner MR, van Heel DA, Vonk Noordegraaf A, Waisfisz Q, Wharton J, Wort SJ, Ouwehand WH, Soranzo N, Lawrie A, Upton PD, Wilkins MR, Trembath RC, Morrell NW.

Nat Commun. 2018 Apr 12;9(1):1416. doi: 10.1038/s41467-018-03672-4.

3.

Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension.

Tamura Y, Phan C, Tu L, Le Hiress M, Thuillet R, Jutant EM, Fadel E, Savale L, Huertas A, Humbert M, Guignabert C.

J Clin Invest. 2018 Apr 9. pii: 96462. doi: 10.1172/JCI96462. [Epub ahead of print]

4.

Rapid Contour-based Segmentation for 18F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation.

Besson FL, Henry T, Meyer C, Chevance V, Roblot V, Blanchet E, Arnould V, Grimon G, Chekroun M, Mabille L, Parent F, Seferian A, Bulifon S, Montani D, Humbert M, Chaumet-Riffaud P, Lebon V, Durand E.

Radiology. 2018 Apr 3:171756. doi: 10.1148/radiol.2018171756. [Epub ahead of print]

PMID:
29613842
5.

Risk assessment in pulmonary arterial hypertension.

Boucly A, Weatherald J, Humbert M, Sitbon O.

Eur Respir J. 2018 Mar 29;51(3). pii: 1800279. doi: 10.1183/13993003.00279-2018. Print 2018 Mar. No abstract available.

PMID:
29599118
6.

Intratumoral CpG-B promotes anti-tumoral neutrophil, cDC, and T cell cooperation without reprograming tolerogenic pDC.

Humbert M, Guery L, Brighouse D, Lemeille S, Hugues S.

Cancer Res. 2018 Mar 27. pii: canres.2549.2017. doi: 10.1158/0008-5472.CAN-17-2549. [Epub ahead of print]

PMID:
29588348
7.

EXPRESS: Riociguat treatment for portopulmonary hypertension: A subgroup analysis from the PATENT-1/-2 studies.

Cartin-Ceba R, Halank M, Ghofrani A, Humbert M, Mattson J, Fritsch A, Krowka M.

Pulm Circ. 2018 Jan 1:2045894018769305. doi: 10.1177/2045894018769305. [Epub ahead of print] No abstract available.

PMID:
29565224
8.

Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.

Humbert M, Taillé C, Mala L, Le Gros V, Just J, Molimard M.

Eur Respir J. 2018 Mar 15. pii: 1702523. doi: 10.1183/13993003.02523-2017. [Epub ahead of print]

PMID:
29545284
9.

Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy.

Huertas A, Guignabert C, Barberà JA, Bärtsch P, Bhattacharya J, Bhattacharya S, Bonsignore MR, Dewachter L, Dinh-Xuan AT, Dorfmüller P, Gladwin MT, Humbert M, Kotsimbos T, Vassilakopoulos T, Sanchez O, Savale L, Testa U, Wilkins MR.

Eur Respir J. 2018 Apr 4;51(4). pii: 1700745. doi: 10.1183/13993003.00745-2017. Print 2018 Apr. Review.

PMID:
29545281
10.

Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension.

Le Hiress M, Akagah B, Bernadat G, Tu L, Thuillet R, Huertas A, Phan C, Fadel E, Simonneau G, Humbert M, Jalce G, Guignabert C.

J Med Chem. 2018 Apr 12;61(7):2725-2736. doi: 10.1021/acs.jmedchem.7b01312. Epub 2018 Mar 19.

PMID:
29526099
11.

Promoting physical activity, healthy eating and gross motor skills development among preschoolers attending childcare centers: Process evaluation of the Healthy Start-Départ Santé intervention using the RE-AIM framework.

Ward S, Chow AF, Humbert ML, Bélanger M, Muhajarine N, Vatanparast H, Leis A.

Eval Program Plann. 2018 Feb 14;68:90-98. doi: 10.1016/j.evalprogplan.2018.02.005. [Epub ahead of print]

PMID:
29505965
12.

[Pulmonary veno-occlusive disease].

Boucly A, Girerd B, Bourlier D, Nemlaghi S, Caliez J, Savale L, Jaïs X, Dorfmüller P, Simonneau G, Sitbon O, Humbert M, Montani D.

Rev Mal Respir. 2018 Feb;35(2):160-170. doi: 10.1016/j.rmr.2017.11.005. Epub 2018 Mar 1. Review. French.

PMID:
29501213
13.

Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry.

Montani D, Henry J, O'Connell C, Jaïs X, Cottin V, Launay D, Habib G, Bourdin A, Jevnikar M, Savale L, Rottat L, Simonneau G, Sitbon O, Humbert M, Allanore Y.

Respiration. 2018;95(4):244-250. doi: 10.1159/000485631. Epub 2018 Feb 28.

PMID:
29490304
14.

NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.

Dumas SJ, Bru-Mercier G, Courboulin A, Quatredeniers M, Rücker-Martin C, Antigny F, Nakhleh MK, Ranchoux B, Gouadon E, Vinhas MC, Vocelle M, Raymond N, Dorfmüller P, Fadel E, Perros F, Humbert M, Cohen-Kaminsky S.

Circulation. 2018 Feb 14. pii: CIRCULATIONAHA.117.029930. doi: 10.1161/CIRCULATIONAHA.117.029930. [Epub ahead of print]

PMID:
29444988
15.

RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study.

Hoette S, Creuzé N, Günther S, Montani D, Savale L, Jaïs X, Parent F, Sitbon O, Rochitte CE, Simonneau G, Humbert M, Souza R, Chemla D.

Lung. 2018 Apr;196(2):157-164. doi: 10.1007/s00408-018-0089-7. Epub 2018 Feb 12.

PMID:
29435740
16.

Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg.

Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA.

Am J Respir Crit Care Med. 2018 Feb 9. doi: 10.1164/rccm.201710-2093PP. [Epub ahead of print]

PMID:
29425462
17.

Respiratory effects of trichloroethylene.

Dumas O, Despreaux T, Perros F, Lau E, Andujar P, Humbert M, Montani D, Descatha A.

Respir Med. 2018 Jan;134:47-53. doi: 10.1016/j.rmed.2017.11.021. Epub 2017 Dec 1. Review.

PMID:
29413507
18.

Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation: role in pulmonary arterial hypertension.

Zurlo G, Piquereau J, Moulin M, Pires Da Silva J, Gressette M, Ranchoux B, Garnier A, Ventura-Clapier R, Fadel E, Humbert M, Lemaire C, Perros F, Veksler V.

J Hypertens. 2018 May;36(5):1164-1177. doi: 10.1097/HJH.0000000000001676.

PMID:
29369849
19.

Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.

Lambert M, Boet A, Rucker-Martin C, Mendes-Ferreira P, Capuano V, Hatem S, Adão R, Brás-Silva C, Hautefort A, Michel JB, Dorfmuller P, Fadel E, Kotsimbos T, Price L, Jourdon P, Montani D, Humbert M, Perros F, Antigny F.

Cardiovasc Res. 2018 Jan 19. doi: 10.1093/cvr/cvy016. [Epub ahead of print]

PMID:
29360952
20.

Dasatinib increases endothelial permeability leading to pleural effusion.

Phan C, Jutant EM, Tu L, Thuillet R, Seferian A, Montani D, Huertas A, Bezu JV, Breijer F, Vonk Noordegraaf A, Humbert M, Aman J, Guignabert C.

Eur Respir J. 2018 Jan 18;51(1). pii: 1701096. doi: 10.1183/13993003.01096-2017. Print 2018 Jan.

PMID:
29348177
21.

Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.

Khouri C, Lepelley M, Roustit M, Montastruc F, Humbert M, Cracowski JL.

Chest. 2017 Dec 21. pii: S0012-3692(17)33265-8. doi: 10.1016/j.chest.2017.12.008. [Epub ahead of print]

PMID:
29275134
22.

Reply to: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter to the Story?

Simonneau G, Humbert M.

Am J Respir Crit Care Med. 2017 Dec 22. doi: 10.1164/rccm.201712-2483LE. [Epub ahead of print] No abstract available.

PMID:
29272591
23.

Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled.

Hemnes AR, Humbert M.

Eur Respir Rev. 2017 Dec 20;26(146). pii: 170093. doi: 10.1183/16000617.0093-2017. Print 2017 Dec 31. Review.

24.

The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?

Weatherald J, Boucly A, Sahay S, Humbert M, Sitbon O.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):860-868. doi: 10.1164/rccm.201709-1840PP. No abstract available.

PMID:
29256625
25.

No genetic association detected with mepolizumab efficacy in severe asthma.

Condreay L, Chiano M, Ortega H, Buchan N, Harris E, Bleecker ER, Thompson PJ, Humbert M, Gibson P, Yancey S, Ghosh S.

Respir Med. 2017 Nov;132:178-180. doi: 10.1016/j.rmed.2017.10.019. Epub 2017 Oct 26.

PMID:
29229094
26.

Care pathways for the selection of a biologic in severe asthma.

Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, Domingo C, Hanania NA, Humbert M, Menzies Gow A, Phipatanakul W, Wahn U, Wechsler ME.

Eur Respir J. 2017 Dec 7;50(6). pii: 1701782. doi: 10.1183/13993003.01782-2017. Print 2017 Dec. No abstract available.

PMID:
29217605
27.

An official European Respiratory Society statement: pulmonary haemodynamics during exercise.

Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, Garcia G, Grünig E, Howard L, Humbert M, Lau E, Laveneziana P, Lewis GD, Naeije R, Peacock A, Rosenkranz S, Saggar R, Ulrich S, Vizza D, Vonk Noordegraaf A, Olschewski H.

Eur Respir J. 2017 Nov 22;50(5). pii: 1700578. doi: 10.1183/13993003.00578-2017. Print 2017 Nov.

PMID:
29167297
28.

Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

da Silva Gonçalves Bós D, Van Der Bruggen CEE, Kurakula K, Sun XQ, Casali KR, Casali AG, Rol N, Szulcek R, Dos Remedios C, Guignabert C, Tu L, Dorfmüller P, Humbert M, Wijnker PJM, Kuster DWD, van der Velden J, Goumans MJ, Bogaard HJ, Vonk-Noordegraaf A, de Man FS, Handoko ML.

Circulation. 2018 Feb 27;137(9):910-924. doi: 10.1161/CIRCULATIONAHA.117.027451. Epub 2017 Nov 22.

PMID:
29167228
29.

Acute decompensated pulmonary hypertension.

Savale L, Weatherald J, Jaïs X, Vuillard C, Boucly A, Jevnikar M, Montani D, Mercier O, Simonneau G, Fadel E, Sitbon O, Humbert M.

Eur Respir Rev. 2017 Nov 15;26(146). pii: 170092. doi: 10.1183/16000617.0092-2017. Print 2017 Dec 31.

30.

Lung transplantation for mitomycin-induced pulmonary veno-occlusive disease.

Savale L, Chaumais MC, Dorfmuller P, Humbert M, Montani D.

Presse Med. 2017 Dec;46(12 Pt 1):1223-1225. doi: 10.1016/j.lpm.2017.09.026. Epub 2017 Nov 10. No abstract available.

PMID:
29129416
31.

Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.

Hammam K, Saez-Ayala M, Rebuffet E, Gros L, Lopez S, Hajem B, Humbert M, Baudelet E, Audebert S, Betzi S, Lugari A, Combes S, Letard S, Casteran N, Mansfield C, Moussy A, De Sepulveda P, Morelli X, Dubreuil P.

Nat Commun. 2017 Nov 10;8(1):1420. doi: 10.1038/s41467-017-01582-5.

32.

TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications.

Olschewski A, Veale EL, Nagy BM, Nagaraj C, Kwapiszewska G, Antigny F, Lambert M, Humbert M, Czirják G, Enyedi P, Mathie A.

Eur Respir J. 2017 Nov 9;50(5). pii: 1700754. doi: 10.1183/13993003.00754-2017. Print 2017 Nov. Review.

PMID:
29122916
33.

Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.

Nossent EJ, Antigny F, Montani D, Bogaard HJ, Ghigna MR, Lambert M, Thomas de Montpréville V, Girerd B, Jaïs X, Savale L, Mercier O, Fadel E, Soubrier F, Sitbon O, Simonneau G, Vonk Noordegraaf A, Humbert M, Perros F, Dorfmüller P.

J Heart Lung Transplant. 2018 May;37(5):647-655. doi: 10.1016/j.healun.2017.09.022. Epub 2017 Oct 4.

PMID:
29108819
34.

A genome-wide association analysis identifies PDE1A|DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population.

Kimura M, Tamura Y, Guignabert C, Takei M, Kosaki K, Tanabe N, Tatsumi K, Saji T, Satoh T, Kataoka M, Kamitsuji S, Kamatani N, Thuillet R, Tu L, Humbert M, Fukuda K, Sano M.

Oncotarget. 2017 Aug 24;8(43):74917-74926. doi: 10.18632/oncotarget.20459. eCollection 2017 Sep 26.

35.

Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.

Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, Jaïs X, Taniguchi Y, O'Connell C, Parent F, Sattler C, Hervé P, Simonneau G, Montani D, Humbert M, Adir Y, Sitbon O.

Circulation. 2018 Feb 13;137(7):693-704. doi: 10.1161/CIRCULATIONAHA.117.029254. Epub 2017 Oct 25.

PMID:
29070502
36.

Controversies and opportunities in severe asthma.

Humbert M, Busse W, Hanania NA.

Curr Opin Pulm Med. 2018 Jan;24(1):83-93. doi: 10.1097/MCP.0000000000000438.

PMID:
29059087
37.

Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.

Boucly A, Cottin V, Nunes H, Jaïs X, Tazi A, Prévôt G, Reynaud-Gaubert M, Dromer C, Viacroze C, Horeau-Langlard D, Pison C, Bergot E, Traclet J, Weatherald J, Simonneau G, Valeyre D, Montani D, Humbert M, Sitbon O, Savale L.

Eur Respir J. 2017 Oct 19;50(4). pii: 1700465. doi: 10.1183/13993003.00465-2017. Print 2017 Oct.

PMID:
29051269
38.

Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Weatherald J, Savale L, Humbert M.

Curr Hypertens Rep. 2017 Oct 18;19(11):86. doi: 10.1007/s11906-017-0783-5. Review.

PMID:
29046979
39.

Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story.

Simonneau G, Humbert M.

Am J Respir Crit Care Med. 2018 Mar 15;197(6):704-706. doi: 10.1164/rccm.201709-1962ED. No abstract available.

PMID:
29043836
40.

Medical Treatment of Pulmonary Arterial Hypertension.

Sahay S, Humbert M, Sitbon O.

Semin Respir Crit Care Med. 2017 Oct;38(5):686-700. doi: 10.1055/s-0037-1607208. Epub 2017 Oct 15. No abstract available.

PMID:
29032569
41.

Evolving Concepts in Pulmonary Hypertension.

Humbert M.

Semin Respir Crit Care Med. 2017 Oct;38(5):559-560. doi: 10.1055/s-0037-1606390. Epub 2017 Oct 15. No abstract available.

PMID:
29032559
42.

Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Humbert M, Singh M, Furst DE, Khanna D, Seibold JR.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v33-v37. doi: 10.1093/rheumatology/kex197. Review.

PMID:
28992168
43.

A unique event for the francophone respiratory community.

Boulet LP, Bissonnette E, Humbert M, Maître B, Pigearias B.

Eur Respir J. 2017 Oct 5;50(4). pii: 1701479. doi: 10.1183/13993003.01479-2017. Print 2017 Oct. No abstract available.

PMID:
28982769
44.

Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL.

Humbert M, Federzoni EA, Tschan MP.

J Leukoc Biol. 2017 Dec;102(6):1357-1370. doi: 10.1189/jlb.1A0317-132R. Epub 2017 Oct 4.

PMID:
28978663
45.

Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.

Hadinnapola C, Bleda M, Haimel M, Screaton N, Swift A, Dorfmüller P, Preston SD, Southwood M, Hernandez-Sanchez J, Martin J, Treacy C, Yates K, Bogaard H, Church C, Coghlan G, Condliffe R, Corris PA, Gibbs S, Girerd B, Holden S, Humbert M, Kiely DG, Lawrie A, Machado R, MacKenzie Ross R, Moledina S, Montani D, Newnham M, Peacock A, Pepke-Zaba J, Rayner-Matthews P, Shamardina O, Soubrier F, Southgate L, Suntharalingam J, Toshner M, Trembath R, Vonk Noordegraaf A, Wilkins MR, Wort SJ, Wharton J; NIHR BioResource–Rare Diseases Consortium; UK National Cohort Study of Idiopathic and Heritable PAH, Gräf S, Morrell NW.

Circulation. 2017 Nov 21;136(21):2022-2033. doi: 10.1161/CIRCULATIONAHA.117.028351. Epub 2017 Sep 28.

46.

Pulmonary hypertension in systemic sclerosis: different phenotypes.

Launay D, Sobanski V, Hachulla E, Humbert M.

Eur Respir Rev. 2017 Sep 27;26(145). pii: 170056. doi: 10.1183/16000617.0056-2017. Print 2017 Sep 30. Review.

47.

Increasing confidence in the therapeutic relevance of eosinophils in severe asthma.

Humbert M.

Lancet Respir Med. 2018 Jan;6(1):7-8. doi: 10.1016/S2213-2600(17)30343-0. Epub 2017 Sep 11. No abstract available.

PMID:
28919199
48.

After asthma: redefining airways diseases.

Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, Cullinan P, Custovic A, Ducharme FM, Fahy JV, Frey U, Gibson P, Heaney LG, Holt PG, Humbert M, Lloyd CM, Marks G, Martinez FD, Sly PD, von Mutius E, Wenzel S, Zar HJ, Bush A.

Lancet. 2018 Jan 27;391(10118):350-400. doi: 10.1016/S0140-6736(17)30879-6. Epub 2017 Sep 11. Review. No abstract available.

49.

Challenging the concept of adding more drugs in pulmonary arterial hypertension.

Dos Santos Fernandes CJC, Humbert M, Souza R.

Eur Respir J. 2017 Sep 9;50(3). pii: 1701527. doi: 10.1183/13993003.01527-2017. Print 2017 Sep. No abstract available.

PMID:
28889116
50.

Are indexed values better for defining exercise pulmonary hypertension?

Weatherald J, Boucly A, Lau E, Godinas L, Savale L, Jaïs X, Montani D, Sitbon O, Simonneau G, Humbert M, Chemla D, Hervé P.

Eur Respir J. 2017 Sep 9;50(3). pii: 1700240. doi: 10.1183/13993003.00240-2017. Print 2017 Sep. No abstract available.

PMID:
28889109

Supplemental Content

Loading ...
Support Center